🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05658081
Recruiting Not applicable

Comparison of Two Stapled Antimesenteric Anastomosis for CD: a Randomized Control Trial Study

NCT05658081 · tracked via the Priya Life Science China tracker
Sponsor
Jinling Hospital, China
Phase
Not applicable
Started
2022-12-08
Last updated
2022-12-20

Condition(s) studied

Crohn DiseaseRecurrence

Investigational drug(s) / intervention(s)

Kono-S groupSide-to-side group

Kono-S group: patients in this arm will receive stapled Kono-S anastomosis after bowel resection

Side-to-side group: patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection

Study summary

The postoperative recurrence of Crohn's diseases (CD) remains high. Stapled anti-mesenteric functional end-to-end anastomosis was safe for CD patients. Its impact on the postoperative recurrence of CD was unknown. Whether it is superior than the conventional anastomosis (stapled antimesenteric isoperistaltic side-to-side anastomosis) needs explored. The trial aims to compare the different impacts of the two antimesenteric anastomosis configurations on the anastomotic recurrence following bowel resection.

Eligibility

Sex
ALL
Min age
16 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * patients with Crohn's disease needing bowel resection and anastomosis; * ileocolic anastomosis; * written consent acquired Exclusion Criteria: * patients underwent enterostomy; * small bowel anastomosis; * anticipating other trial.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of General Surgery, Jinling hosptal,Medical School of Nanjing University Nanjing Jiangsu Recruiting

More Jinling Hospital, China trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05658081 on ClinicalTrials.gov ↗ ← All trials in China